Subchondral and intra-articular injections of bone marrow concentrate are a safe and effective treatment for knee osteoarthritis: a prospective, multi-center pilot study

• Published in: Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA Vol. 29; no. 12; pp. 4232 - 4240
• Main Authors: Kon, Elizaveta, Boffa, Angelo, Andriolo, Luca, Di Martino, Alessandro, Di Matteo, Berardo, Magarelli, Nicola, Marcacci, Maurilio, Onorato, Francesco, Trenti, Nicoletta, Zaffagnini, Stefano, Filardo, Giuseppe
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2021; Springer Nature B.V
• Subjects: Biomedical materials; Bone marrow; Complications; Edema; Knee; Magnetic resonance imaging; Medicine; Medicine & Public Health; Orthopedics; Osteoarthritis; Pain; Patients; Safety; Sports Medicine; Subchondral bone; Knee; Intra-articular; Subchondral; BMAC; Bone marrow; Injective; Osteoarthritis
• ISSN: 0942-2056; 1433-7347
• DOI: 10.1007/s00167-021-06530-x

Purpose Subchondral bone is becoming a treatment target for knee OA patients, with promising early findings on the use of bone marrow aspirate concentrate (BMAC). The aim of this prospective, multi-centric pilot study was to evaluate safety as well as clinical and MRI outcomes of a combined approach of intra-articular and subchondral BMAC injections. Methods Thirty patients (19 men, 11 women, 56.4 ± 8.1 years) with symptomatic knee OA were treated with a combination of an intra-articular and two subchondral BMAC injections (femoral condyle and tibial plateau). Patients were evaluated at baseline and at 1–3–6–12 months of follow-up with the IKDC subjective, VAS, KOOS, and EQ-VAS scores. The MRI evaluation was performed with the WORMS score. Results No major complications were reported and only two patients were considered treatment failures, requiring a new injective or surgical treatment. The IKDC subjective score improved significantly from 40.5 ± 12.5 to 59.9 ± 16.1 at 3 months, 59.1 ± 12.2 at 6 months, and 62.6 ± 19.4 at 12 months ( p  < 0.0005). A similar improvement was reported for VAS pain and all KOOS subscales at all follow-ups, while EQ-VAS did not show any significant improvement. The MRI analysis showed a significant bone marrow edema reduction ( p  = 0.003), while the remaining WORMS parameters did not show any significant changes. Conclusion The pilot evaluation of this combined BMAC injective treatment showed safety and positive outcome up to 12 months of follow-up in patients with symptomatic knee OA associated with subchondral bone alterations. These findings suggest that targeting both subchondral bone and joint environment can provide promising results, and that BMAC can be a valid option for this combined approach to treat knee OA.